Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death.
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death. Patients with peritoneal metastasis have a worse prognosis than patients with metastatic disease at other sites. Without treatment, the median survival in patients with peritoneal metastasis from gastric cancer is 1–3 months. Average median overall survival ranges from 4.3 months to 11 months, and is better with a combination of chemotherapy agents.
Periotnectomy and HIPEC in Gastric cancer provides long term survival in selected patients with gastric cancer and peritoneal metastasis. Peritonectomy and HIPEC should be considered for some gastric Peritoneal metastasis as curative approach.
Post peritonectomy and HIPEC will provide the median survival of 11- 43.4 months and 5-years survival rate ranged up to to 31%.
The 2 most important prognostic factors are:
- Complete cytoreductive surgery CC-0.
- PCI less than 10.
- No evidence of distant metastasis.
Laparoscopy may help to appreciate disease extension and patient’s selection.
What is the prognosis?
Gastric (stomach) cancer has also been treated by peritonectomy and HIPEC. An Asian randomised trial has demonstrated that the addition of HIPEC to surgery improves survival for newly diagnosed cancer with low volume peritoneal disease. In our experience very few individuals present with a low enough PCI to justify this treatment. Please ask us if you need further information about this treatment for stomach cancer.